Raltegravir: The first HIV Type 1 Integrase Inhibitor

Clinical Infectious Diseases

Volumn 48, Issue 7, 2009, Pages 931-939

  Hicks, Charles ^a   Gulick, Roy M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LAMIVUDINE; METHADONE; MIDAZOLAM; NEVIRAPINE; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INJECTION SITE REACTION; NAUSEA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOCYTE; VIRUS DNA CELL DNA INTERACTION; VIRUS LOAD;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INTEGRASE INHIBITORS; PYRROLIDINONES;

EID: 63649087422     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597290     Document Type: Article

References (38)

1. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50.
2. Isentress (raltegravir) [package insert]. Whitehouse Station, NJ: Merck, 2007.
3. Hazuda DJ, Felock PJ, Hastings JC, Pramanik B, Wolfe AL. Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol 1997;71:7005-11.
4. Yoder KE, Bushman FD. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000;74:11191-200.
5. Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type-1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78:5045-55.
6. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4:236-48.
7. Petry AS, Wenning LA, Laethem M, et al. Safety, tolerabililty, and pharmacokinetics after single and multiple doses of MK-0518 inhealthy subjects [abstract A-376]. In: Program and abstracts of 46th Intersci- ence Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
8. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Dene Syndr 2006;43:509-15.
9. Kassahun K, Mcintosh I, Hreniuk D, et al. Absorption, metabolism, and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers [abstract A-372]. In: Program and abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
10. Iwamoto M, Kassahan K, Matthew D, et al. Lack of pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008;48:209-14.
11. Iwamoto M, Wenning L, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy adults. Clin Infect Dis 2008;47:137-40.
12. Wenning L, Friedman K, Kost J, et al. Lack of a significant drug interaction between MK-0518 and tenotbvir disoproxil fumarate [abstract A-0375]. In: Program and abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
13. Iwamoto M. Wenning L, Petry A, et al. Minimal effect of ritonavir and efavirenz on the pharmacokinetics of MK-0518 [abstract A-0373]. In: Program and abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
14. Anderson M, Kakuda T, Miller J, et al. Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects [abstract TuPDB02[. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (Sydney, Australia). 2007.
15. Wenning L, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir on pharmacokinetics of MK-0518 [abstract A-0374]. In: Program and abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
16. Khanlou H, Allavena C, Billaud E, McKellar M, Reliquet V. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranvir/rito- navir [abstract TuPE0087|. In: Program and abstracts of the XVII International AIDS Conference (Mexico City). 2008.
17. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable an- tiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Dene Syndr 2007;46:125-33.
18. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1-infected patients: 96-week data [abstract TuAB0102J. In: Program and abstracts of the XVII International AIDS Conference (Mexico City). 2008.
19. Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, a phase III study of the safety & efficacy of raltegravir (RAL)-based vs efavirenz (EFV)- based combination therapy in treatment-naive HIV-infected patients [abstract H-896a[. In: Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2008.
20. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9.
21. Grinsztejn B, Nguyen B, Katlama C, et al. 48-Week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple- class resistant virus [abstract H-713], In: Program and abstracts of 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
22. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54.
23. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65.
24. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21:2315-21.
25. Harris M, Larsen G, Montaner J. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22:1224-6.
26. Towner W, Klein D, Follansbee S, et al. Pilot study of switching enfuvirtide to raltegravir in HIV-1 positive patients well controlled on an enfuvirtide-based regimen [abstract TuPE0115[. In: Program and abstracts of the XVII International AIDS Conference (Mexico City), 2008.
27. Talbot A, Machouf N, Thomas R, et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal cohort [abstract TuPEOl 12]. In: Program and abstracts of the XVII International AIDS Conference (Mexico City). 2008.
28. Merck Research Laboratories. Briefing Document-FDA Antiviral Drugs Advisory Committee Meeting. Isentress (raltegravir) 400 mg for treatment of HIV (NDA 22-145). 5 September 2007. Available at http: //www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4314bl-01-Merck.pdf. Accessed 10 February 2009.
29. Zembower T, Gerzenshten L, Colemen K, Palella F. Severe rhabdomyol- ysis associated with raltegravir use. AIDS 2008;22:1382-4.
30. Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22:1890-2.
31. Elspeth A, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci 2000;97:11244-9.
32. Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV- integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Therapy 2007; 12;S10.
33. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;51:1351-8.
34. Jones G, Ledford RM, Yu F, et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 JTK-303) [abstract 627]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Washington, DC: American Society for Microbiology, 2007.
35. DeJesus E, Cohen C, Elion R, et al. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137) [abstract TuPEB032]. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (Sydney, Australia). 2007.
36. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 2007;12;S11.
37. Panel on Antiretroviral Guidelines tor Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008:1-128. Available at http://www.aidsinfo.nih.gov/Content Files/AdultandAdolescentGL.pdf. Accessed 3 November 2008.
38. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24 [ abstract 70aLB ]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Agents (Montreal). 2009.